引用次数
引用: 2,954
H-指数: 25
I10-指数 : 45
出版物: 88
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
Stephen J Ruberg , Lei Chen , Virginia Stauffer , Haya Ascher-Svanum
BMC Psychiatry 11 ( 1) 23 -23
16
2011
The mean does not mean as much anymore: finding sub-groups for tailored therapeutics:
Stephen J Ruberg , Lei Chen , Yanping Wang
Clinical Trials 7 ( 5) 574 -583
88
2010
Efficiency of Two Sample Tests via the t-Mean Survival Time for Analyzing Event Time Observations
Lu Tian , Haoda Fu , Stephen J Ruberg , Hajime Uno
bepress
2016
Statistical inference on the estimators of the adherer average causal effect
Ying Zhang , Haoda Fu , Stephen J Ruberg , Yongming Qu
Statistics in Biopharmaceutical Research 14 ( 3) 392 -395
1
2022
Assessing the commonly used assumptions in estimating the principal causal effect in clinical trials
Yongming Qu , Ilya Lipkovich , Stephen J Ruberg
Statistics in Biopharmaceutical Research 15 ( 4) 812 -819
3
2023
Selection bias in the treatment effect for a principal stratum
Yongming Qu , Stephen J Ruberg , Junxiang Luo , Ilya Lipkovich
arXiv preprint arXiv:2112.09541
2021
Application of Bayesian approaches in drug development: starting a virtuous cycle
Stephen J Ruberg , Francois Beckers , Rob Hemmings , Peter Honig
Nature Reviews Drug Discovery 22 ( 3) 235 -250
28
2023
A resampling-based ensemble tree method to identify patient subgroups with enhanced treatment effect
Chakib Battioui , Lei Shen , Stephen J Ruberg
Proceedings of 2014 joint statistical meetings 4013 -4023
11
2014
Detente: a practical understanding of p values and Bayesian posterior probabilities
Stephen J Ruberg
Clinical Pharmacology & Therapeutics 109 ( 6) 1489 -1498
10
2021
Robust data analysis
Robert V Hogg , Stephen J Ruberg , Lianng Yuh
CRC Press 371 -402
9
2016
Estimating the treatment effect for adherers using multiple imputation
Junxiang Luo , Stephen J Ruberg , Yongming Qu
Pharmaceutical Statistics 21 ( 3) 525 -534
5
2022
Integrated Electronic Solutions.
Stephen J Ruberg , Michael McDonald , Maury Wolfred
Applied Clinical Trials 11 ( 2)
2
2002
Teaching Statistics for Understanding and Practical Use
Stephen J Ruberg
Biopharmaceutical Report 1 1 -4
2
1992
Accurate collection of reasons for treatment discontinuation to better define estimands in clinical trials
Yongming Qu , Robin D White , Stephen J Ruberg
Therapeutic Innovation & Regulatory Science 57 ( 3) 521 -528
1
2023
A qUESTION OF
Mike Murphy , Stephen J Ruberg
TLS-THE TIMES LITERARY SUPPLEMENT ( 6253) 25 -25
2023
A Bayesian Posterior Probability Is the Real Replication Probability
Stephen J Ruberg
Statistics in Biopharmaceutical Research 13 ( 1) 49 -54
2020
directional decision for a two-tailed alternative
Stephen J Ruberg
Marcel Dekker, Inc. 6 ( 2) 215 -215
1996
Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".
J Sahai , D P Healy , M J Shelton , J S Miller
Antimicrobial Agents and Chemotherapy 34 ( 5) 765 -769
56
1990
Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.
J A Smithers , H K Kulmala , G A Thompson , K K Antony
Antimicrobial Agents and Chemotherapy 36 ( 1) 115 -120
18
1992
Confidence intervals associated with tests for bioequivalence
J. C. HSU , J. T. G. HWANG , H.-K. LIU , S. J. RUBERG
Biometrika 81 ( 1) 103 -114
71
1994